Screener
Pfizer PFE Available For Sale Securities Debt Securities Current
Available For Sale Securities Debt Securities Current at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: Pfizer’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000078003-26-000054
| (MILLIONS) | March 29,2026 | December 31, 2025 |
|---|---|---|
| Short-term investments | ||
| Equity securities with readily determinable fair values | $1,865 | $2,596 |
| Available-for-sale debt securities | 8,189 | 9,183 |
| Held-to-maturity debt securities | 1,318 | 675 |
| Total Short-term investments | $11,372 | $12,454 |
| Long-term investments | ||
| Equity securities with readily determinable fair values(a) | $653 | $642 |
| Available-for-sale debt securities | — | 1 |
Item 1.
FAQ
- What is Pfizer's available for sale securities debt securities current?
- Pfizer (PFE) reported available for sale securities debt securities current of $8.19B in Q1 2026.
- How has Pfizer's available for sale securities debt securities current changed year-over-year?
- Pfizer's available for sale securities debt securities current decreased by 41.3% year-over-year, from $13.95B to $8.19B.
- What is the long-term trend for Pfizer's available for sale securities debt securities current?
- Over 5 years (2020 to 2025), Pfizer's available for sale securities debt securities current has grown at a -1.1% compound annual growth rate (CAGR), from $9.71B to $9.18B.
Ask your AI about Pfizer's available for sale securities debt securities current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude